Modification and Characterization of Gellan Gum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Modification and Characterization of Gellan Gum
The authors modified gellan gum using microwave technology and showed it can be used as an excipient in tablet formulations.


Pharmaceutical Technology
Volume 33, Issue 7, pp. 48-58

10. A. Rozier et al., "Functionality Testing of Gellan Gum, a Polymeric Excipient Material for Ophthalmic Dosage Forms," Int. J. Pharm. 153 (2), 191–198 (1997).

11. Y.D. Sanzgiri et al., "Gellan-Based Systems for Ophthalmic Sustained Delivery of Methylprednisolone," J. Control. Release 26 (3), 195–201 (1993).

12. S. Miyazaki et al., "In Situ Gelling Gellan Formulatons as Vehicles for Oral Delivery," J. Control. Release 60 (2–3), 287–295 (1999).

13. S. Miyazaki et al., "Comparison of in situ gelling formulations for the oral delivery of cimetidine," Int. J. Pharm. 220 (1–2), 161–168 (2001).

14. F. Kedzierewicz et al., "Effect of the Formulation on the In Vitro Release of Propranolol from Gellan Beads," Int. J. Pharm. 178 (1), 129–136 (1999).

15. E. Santucci et al., "Gellan for the Formulation of Sustained Delivery Beads," J. Control. Release 42 (2), 157–164 (1996).

16. T. Coviello et al., "A Novel Co-Crosslinked Polysaccharide: Studies for a Controlled Delivery Matrix," J. Control. Release 55 (1), 57–66 (1998).

17. P.S. Rajnikanth, J. Balasubramaniam, and B. Mishra, "Development and Evaluation of a Novel Floating In Situ Gelling System of Amoxicillin for Eradication of Helicobacter pylori," Int. J.Pharm. 335 (1–2), 114–122 (2007).

18. N. Vatanasuchart et al., "Molecular Properties of Cassava Starch Modified with Different UV Radiations to Enhance Baking Expansion," Carbohydrate Polymers 61 (1), 80–87 (2005).

19. A.K. Mubarak et al., "Preparation and Characterzaton of Ultraviolet (UV) Radiaton-Cured Biodegradable Films of Sago Starch/PVA Blend," Carbohydrate Polymer 63 (4), 500–506 (2006).

20. G.D. Kashappa and J.P. Hyun, "Study of Gamma-Irradiation Effects on Chitosan Micropartcles," Drug Delivery 13 (1), 39–50 (2006).

21. V. Micard et al., "Properties of Chemically and Physically Treated Wheat Gluten Films," J. Agric. Food Chem. 48 (7), 2948–2953 (2000).

22. H. Vromans, "Microwave Drying of Pharmaceutical Excipients: Comparison with Conventional Conductive Drying," Eur. J. Pharm. Biopharm. 40 (5), 333–336 (1994).

23. C. Doyle and M.J. Cliff, "Microwave Drying for Highly Active Pharmaceutical Granules," Mfg. Chemist 58 (2), 23–25 (1987).

24. M.K. Doelling and R.A. Nash, "The Development of a Microwave Fluid-Bed Processor: II. Drying Performance and Physical Characteristics of Typical Pharmaceutical Granulations," Pharm. Res. 9(11), 1493–1501 (1992).

25. T.K. Mandal, "Evaluation of Microwave Drying for Pharmaceutical Granulations," Drug Dev. Ind. Pharm. 21 (14), 1683–1688 (1995).

26. G. Duschler, W. Carius, and K.H. Bauer, "Single Step Granulation Method with Microwave: Preliminary Studies and Pilot-Scale Results," Drug Dev. Ind. Pharm. 21 (14), 1599–1610 (1995).

27. H.N. Joshi, M.A. Kral, and E.M. Topp, "Microwave Drying of Aqueous Tablet Film Coatings: A Study on Free Film," Int. J. Pharm. 51 (1), 19–25 (1989).

28. K. Sasaki, W. Honda, and Y. Miyake, "Evaluation of High-Temperature and Short-Time Sterilization of Injection Ampules by Microwave Heating," J. Pharm. Sci. Technol. 52 (1), 5–12 (1998).

29. T.W. Wong et al., "Design of Controlled-Release Solid Dosage forms of Alginate and Chitosan using Microwave," J. Control. Release 84 (3), 99–114 (2002).

30. H. Khalil and T. Villota, "Comparative Study on Injury and Recovery of Staphylococcus aureus using Microwaves and Conventional Heating," J. Food Prod. 51 (3), 181–186 (1988).

31. D.D. Pomerai et al., "Nonthermal Heat Shock Response to Microwaves," Nature 405, 417–418 (2000).

32. F.E. Bowen, and W.A. Vadino, "A Simple Method for Differentiating Sources of Pregelatinized Starch NF," Drug Dev. Ind. Pharm. 10 (3), 505–514 (1984).

33. M.E. Aulton, Pharmaceutics: The Science of Dosage Form Design (Churchill Livingstone, 2nd ed., New York, NY, 2002).

34. G.S. Banker and N.R. Anderson, "Tablets," in The Theory and Practice of Industrial Pharmacy, L. Lachman, H.A. Liebermann, and J.L. Kanig, Eds. (Varghese Publishing House, 3rd. ed., Bombay, India, 1987), pp. 293-345.

35. K. Stefan et al., "Structural Aspects and Phase Behavious in Deacylated and High Acyl Gellan Systems," Carbohydrate Polymers 38 (2), 145–154 (1999).

36. H. Yiqum et al., "Gelling Temperature of High Acyl Gellan Affected by Monovalent and Divalent Cations with Dynamic Rheological Analysis," Carbohydrate Polymers 56 (1), 27–33 (2004).

37. K.T.G. Kelvin, R.H. Derek, and S. Harjinder, "Characterisation of a High Acyl Gellan Polysaccharides using Light Scattering and Rheological Techniques," Food Hydrocolloids 20 (2–3), 176–183 (2006).

38. S. Bolton and B. Charles, Pharmaceutical Statistics: Practical and Clinical Application (Marcel Dekker, New York, NY, 2004).

39. M. Rios, "Developments in Powder Flow Testing," Pharm. Technol. 30 (2), 38–49 (2006).

40. United States Pharmacopoeia 29–National Formulary 24 (US Pharmacopoeial Convention, Rockville, MD, 2006).

41. M.C. Gohel et al., "Improving the Tablet Characteristics and Dissolution Profile by using a Novel Coprocessed Superdisintegrant: A Technical Note," AAPS PharmSciTech. 8, E1–E6 (2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
21%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
8%
Regulatory compliance
42%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here